C3 launch in Europe

CLINICAL Cell Culture (C3) commercially launched its CellSpray XP product in Europe this week. The local company expects the first patients to be treated with the product by the end of June or early July this year. C3 estimates the European market potential for the products to be approximately 10,000 patients a year. Using proprietary tissue-culture technology, C3 provides treatment solutions derived from a patient’s own skin to enhance healing rates, reduce scar formation and reintroduce pigmentation to the skin.

Add your comment

BNIQ sponsored byECU School of Business and Law


6th-Australian Institute of Management WA20,000
7th-Murdoch University16,584
8th-South Regional TAFE10,549
9th-Central Regional TAFE10,000
49 tertiary education & training providers ranked by total number of students in WA

Number of Employees

BNiQ Disclaimer